AIDS Vaccines: The Next Frontiers

The AIDS Vaccine Advocacy Coalition on Thursday released its annual report, titled "AIDS Vaccines: The Next Frontiers," which says that without sufficient future planning, AIDS vaccine research could be slowed.

The report -- which lists critical steps to ensure that goals in HIV/AIDS prevention technologies, including AIDS vaccines, are met -- summarizes issues and challenges in developing HIV/AIDS prevention technologies.

"Planning for different scenarios for AIDS prevention at this stage is essential," Mitchell Warren, executive director of AVAC, said, adding, "Without adequate planning and coordination, the issues which will emerge as one or more interventions show signs of some efficacy could slow the pace of future studies.

And we must simultaneously lay the groundwork now to ensure new prevention methods reach the people who need them most."

The report includes an update on AIDS vaccine science and funding; an analysis of successes and challenges in the search for an AIDS vaccine; a look into how the licensing and distribution of the HPV vaccine can inform future AIDS vaccine initiatives; and an outline of future challenges in AIDS vaccine developments (AVAC release, 9/14).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Public trust in COVID-19 vaccine science influences vaccine uptake in the US